{"entity":{"id":"catnon","kind":"trial","name":"CATNON (EORTC 26053-22054)","aka":[],"tldr":"CATNON showed that a year of temozolomide after radiotherapy lengthens survival in anaplastic gliomas that lack the 1p/19q co-deletion, and that the benefit is concentrated in IDH-mutant tumours.","summary":"CATNON randomised 751 adults with newly diagnosed 1p/19q non-co-deleted anaplastic glioma in a two-by-two design to radiotherapy alone, with concurrent temozolomide, with 12 cycles of adjuvant temozolomide, or both. Adjuvant temozolomide improved overall survival (hazard ratio 0.65 in the interim analysis; five-year survival 55.9 vs 44.1 percent), while concurrent temozolomide did not in the tumours as a whole and helped only IDH-mutant tumours (van den Bent and colleagues, Lancet 2017 and Lancet Oncology 2021).","status":"positive","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT00626990","url":"https://clinicaltrials.gov/study/NCT00626990"},{"label":"Lancet 2017","url":"https://doi.org/10.1016/S0140-6736(17)31442-3"}],"tags":["radiation-wave2"],"related":[],"cancers":["glioblastoma","brain-tumours","idh-mutant-astrocytoma"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["temozolomide"],"companies":["curie-nki-eortc"],"institutions":[],"pathways":[],"terms":["chemoradiation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00626990","phase":"3","setting":"Newly diagnosed anaplastic glioma without 1p/19q co-deletion: radiotherapy with or without concurrent and with or without adjuvant temozolomide","sponsor":"EORTC","result":"Adjuvant temozolomide: overall survival hazard ratio 0.65; 5-year survival 55.9% vs 44.1%. Concurrent temozolomide benefit confined to IDH-mutant tumours.","started":"2007-12","startedType":"actual","yearReported":2017,"enrolled":751,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival at 5 years","primary":true,"unit":"%","arms":[{"name":"Adjuvant temozolomide","value":55.9,"note":"Interim analysis after 219 deaths, 745 patients enrolled; hazard ratio 0.65 with 99.145% CI 0.45-0.93"},{"name":"No adjuvant temozolomide","value":44.1}],"hr":0.65,"source":"https://doi.org/10.1016/S0140-6736(17)31442-3"}]},"route":"/trials/catnon/","neighbours":{"cancer":[{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/"},{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/"}],"term":[{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"}],"paper":[{"id":"paper-catnon-lancet-2017","kind":"paper","name":"CATNON: concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion","route":"/key-papers/paper-catnon-lancet-2017/"}]}}